PDCD1 and neoplasm: In addition, more PD‐1 ICB resistance was seen during immunotherapy in patients with hepatocellular carcinoma [5], the efficacy of immunotherapy remains uncertain, potentially attributed to suppressed tumour microenvironments [6, 7] and immune evasion [8].